BIOXYTRAN, INC (BIXT) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US09075D1028

Price
0.02 USD
Market cap
2.64 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
81.93 %
Return on assets (ROA)
-322.39 %

BIOXYTRAN, INC financials

Fiscal year20242025
Operating income-2.22 m USD-1.84 m USD
EBIT-2.30 m USD-1.99 m USD
Net income-2.37 m USD-2.12 m USD
Diluted EPS – continuing operations-0.02 USD-0.02 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About BIOXYTRAN, INC

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-3, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.